MapLight Therapeutics (MPLT) Income towards Parent Company (2024 - 2025)
MapLight Therapeutics (MPLT) reported Income towards Parent Company of -$81.2 million for Q4 2025, down 276.34% on a YoY basis from $46.1 million in Q4 2024, and down 138.36% sequentially from -$34.1 million in Q3 2025.
MapLight Therapeutics (MPLT) Income towards Parent Company (2024 - 2025) Analysis & Trends
MapLight Therapeutics (MPLT) has 2 years of Income towards Parent Company data on file, last reported at -$81.2 million in Q4 2025.
- For the quarter ending Q4 2025, Income towards Parent Company fell 276.34% year-over-year to -$81.2 million; the trailing twelve-month figure through Dec 2025 stood at -$157.0 million (changed N/A YoY), and the FY2025 full-year result was -$176.2 million, down 93.77% from the prior year.
- Income towards Parent Company retreated to -$81.2 million in Q4 2025, from -$34.1 million in the prior quarter.
- In the past five years, Income towards Parent Company ranged from a high of -$20.1 million in Q3 2024 to a low of -$81.2 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - |
| 10 | MapLight Therapeutics | 314.07 Mn | 314.07 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -81.21 Mn |
| Sep 30, 2025 | -34.07 Mn |
| Dec 31, 2024 | -21.58 Mn |
| Sep 30, 2024 | -20.11 Mn |